PUBLICATIONS
- Arceri V, Kane MP. Hyperthyroidism. 在药物治疗原则和实践研究指南:基于病例的护理计划方法, 第6版(Chisholm-Burns等人的第6版的配套教科书). Pharmacotherapy Principles and Practice); Sept 2022.
- Kane MP, Bakst G. Thyroid Disorders. 在DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. Pharmacotherapy: A Pathophysiologic Approach, 12e New York, NY: McGraw-Hill; 2022; Chapter 96: Thyroid Disorders; 1-50.
- Cibotaru D, Celestin MN, Kane MP, Musteata M. Comparison of Liquid-Liquid Extraction, Microextraction, 超滤法测定睾酮和苯妥英游离浓度. Bioanalysis. 2022;14(4): 195-204.
- Quinn HB, Busch RS, Kane MP. 门诊内分泌科低磷血症的发生与负担. Endocrine Practice, 2021;27:1189-1192.
- Cibotaru D, Celestin MN, Kane MP, Musteata M. 同时测定游离浓度的方法, Total Concentration, and Plasma Binding Capacity in Clinical Samples. J Pharm Sci 2021;110:1401-11.doi: 10.1016/j.xphs.2020.12.001.
- Kane MP, Triplitt C, Solis-Herrera C. 口服西马鲁肽治疗2型糖尿病:药师实用指南. Am J Health Syst Pharm . 2021 Mar 18;78(7):556-567. doi: 10.1093/ajhp/zxaa413.
- Kane MP, Bakst G. Thyroid disorders. In: DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V,等. Pharmacotherapy: A Pathophysiologic Approach, 11ed. New York, NY: McGraw-Hill Education, 2019.
- Kane MP, Triplitt C, Solis-Herrera C. 口服西马鲁肽治疗2型糖尿病:药师实用指南. 接受发表,美国卫生系统药学杂志.
- Kuchis MM, Eldeiry A, Busch RS, Racz MJ, Kane MP. 蛋白转化酶Subtilisin/Kexin Type 9 (PCSK9)抑制剂的长期安全性和有效性. Endocr Pract (Abstract). 2020;26(suppl 2):166-167.
- 治疗学ACCP/ASHP门诊护理药学预备审查和再认证课程的更新, 2020 ed. 张志强,张志强,张志强,等。美国临床药学杂志,2008:47-108.
- Kuchis M, Kane MP. 亚临床甲状腺功能减退:不要让数字欺骗你:左甲状腺素不是万灵药. March 3, 2020 http://iforumrx.org/commentary/don%E2%80%99t-let-numbers-fool-you-levo..。
- McGreevy JL, Kane MP, Busch RS, Bakst G, ElDeiry SS. 药剂师经营的合成代谢骨质疏松症诊所:阿巴巴拉肽描述性报告. J Am Pharm Assoc. 2019;59(4):593-597.
- Kane MP, Bakst G. Thyroid disorders. In: DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V,等. Pharmacotherapy: A Pathophysiologic Approach, 11ed. New York, NY: McGraw-Hill Education, 2019.
- Farina K, Kane MP. 程序性细胞死亡-1单克隆抗体治疗与1型糖尿病:文献综述. J Pharm Pract. 2019 Jul 3:897190019850929. doi: 10.1177/0897190019850929
- Endocrine Disorders. In: Bainbridge JL, Cardone K, Cross LB, et al. 治疗学ACCP/ASHP门诊护理药学预备审查和再认证课程的更新, 2019 ed. 张志强,张志强。美国临床药学杂志,2019:631-93.
SELECTED POSTER/PLATFORM PRESENTATIONS
- Arceri V, Kane MP, Quinn HB, Telese M, Racz M, Busch RS. 阿巴巴拉肽的实施和随访:药剂师经营的合成代谢骨质疏松症诊所的实际结果. 海报于2022年6月11日在佐治亚州亚特兰大举行的2022内分泌学会年会上公布.
- Updates in Diabetes Management: The Elderly. 在纽约美国咨询药剂师协会中州分会会议上发表, Syracuse, NY, June 1, 2022.
- 骨质疏松症不断发展的治疗范式:药剂师在优化护理中的整体作用. Pharmacy Times CE, Cranbury, NJ, April 27, 2022.
- Quinn HB, Busch RS, Kane MP. 摘要编号:8734内分泌学会年会. 摘要题目:门诊内分泌科低磷酸症的患病率和负担. Poster session: P08. Parathyroid and Rare Bone Disorders. Took place online, ENDO 2021, March 20-23, 2021.
- PSSNY/CPESN糖尿病自我护理管理(DSMES)训练营. 糖尿病最新进展:药物、临床指南和治疗建议. Presented Nov 8, 2020, virtual presentation.
- Kuchis MM, Eldeiry A, Busch RS, Racz M, Kane MP. 蛋白转化酶枯草素/kexin 9型(PCSK9)抑制剂的长期安全性和有效性. EMBRAACE 2020: The AACE 29th Annual Scientific & Clinical Congress; Washington, DC May 10, 2020. (On-line presentation due to COVID-19 pandemic).
- ACCP/ASHP 2020 Ambulatory Care Pharmacy Preparatory Review and Recertification Course; Endocrine Disorders. Presented March 5, 2020, Henderson, NV.
- Current Issues in Hypothyroidism. 护士执业协会纽约州第35届年会. Presented October 19, 2019, Verona, NY.
- ACCP/ASHP 2019 Ambulatory Care Pharmacy Preparatory Review and Recertification Course; Endocrine Disorders. Presented May 3, 2019, Minneapolis, MN.
- McGreevy JL, Cherian S, Kane MP, Busch RS, Racz M. A real-world GLP-1 receptor agonist switch study. 在2019年治疗学ACCP/ASHP更新会议上发表. Louis College of Pharmacy, St. Louis, Missouri, April 28, 2019.
RESEARCH GRANTS
阿巴巴拉肽的实施和随访:药剂师经营的合成代谢骨质疏松症诊所的实际结果. Kane MP, Arceri V, Quinn H, Busch RS. Radius Pharmaceuticals, $42,640; Dec 2021.
在门诊护理内分泌实践中低磷血症的患病率和负担. Kane MP, Quinn H, Busch RS. Awarded $42,640; Alexion Pharmaceuticals; July 2020.
同时测定游离、总和标准化浓度的生物活性化合物. Musteata FM, Kane MP. National Institutes of Health. Grant Number: 1R15GM126510-01 FAIN: R15GM126510. Awarded $480,000. 09/01/2018 – 08/31/2021.